Rabbit anti-Human AVPR2 Polyclonal Antibody

Uniprot Id

P30518

Target Species

Human

Target Name

AVPR2

Target Full Name

Vasopressin V2 receptor

Target Function

Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.

Target Involvement

Nephrogenic syndrome of inappropriate antidiuresis (NSIAD); Diabetes insipidus, nephrogenic, X-linked (XNDI)

Target Subcellular Location

Cell membrane; Multi-pass membrane protein.

Target Protein Families

G-protein coupled receptor 1 family, Vasopressin/oxytocin receptor subfamily

Target Tissue Specificity

Kidney.

Target Synonyms

ADHR; Antidiuretic hormone receptor; Arginine vasopressin receptor 2; AVP R2; AVPR 2; AVPR V2; AVPR2; DI1; DIR 3; DIR; DIR3; MGC126533; MGC138386; NDI; Nephrogenic diabetes insipidus; Renal type arginine vasopressin receptor; Renal-type arginine vasopressin receptor; V2 receptor; V2R; V2R_HUMAN; Vasopressin V2; Vasopressin V2 receptor

Target Background

This gene encodes the vasopressin receptor, type 2, also known as the V2 receptor, which belongs to the seven-transmembrane-domain G protein-coupled receptor (GPCR) superfamily, and couples to Gs thus stimulating adenylate cyclase. The subfamily that includes the V2 receptor, the V1a and V1b vasopressin receptors, the oxytocin receptor, and isotocin and mesotocin receptors in non-mammals, is well conserved, though several members signal via other G proteins. All bind similar cyclic nonapeptide hormones. The V2 receptor is expressed in the kidney tubule, predominantly in the distal convoluted tubule and collecting ducts, where its primary property is to respond to the pituitary hormone arginine vasopressin (AVP) by stimulating mechanisms that concentrate the urine and maintain water homeostasis in the organism. When the function of this gene is lost, the disease Nephrogenic Diabetes Insipidus (NDI) results. The V2 receptor is also expressed outside the kidney although its tissue localization is uncertain. When these 'extrarenal receptors' are stimulated by infusion of a V2 selective agonist (dDAVP), a variety of clotting factors are released into the bloodstream. The physiologic importance of this property is not known - its absence does not appear to be detrimental in NDI patients. The gene expression has also been described in fetal lung tissue and lung cancer associated with alternative splicing.